39944-62-2

Basic information

• Product Name: 2,4,5,6-Tetraaminopyrimidine dihydrochloride
• Synonyms: 2,4,5,6-Tetraaminopyrimidine2HCL;pyriMidine-2,4,5,6-tetraMine dihydrochloride;2,4,5,6-TetraaMinopyriMidine diydrochloride;Pyrimidine-2,4,5,6-tetraamine dihydrochloride;2,4,5,6-Tetraaminopyrimidine dihydrochloride;Pyrimidinetetramine, hydrochloride
• CAS NO: 39944-62-2
• Molecular Formula: C₄H₈N₆*2ClH
• Molecular Weight: 213.07
• EINECS: 1533716-785-6
• Product Categories: Pyrimidines
• Mol File: 39944-62-2.mol

Chemical Properties

• Boiling Point: 534.9ºC at 760 mmHg
• Flash Point: 277.3°C
• Appearance: /
• Vapor Pressure: 8.68E-12mmHg at 25°C
• CAS DataBase Reference: 2,4,5,6-Tetraaminopyrimidine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,5,6-Tetraaminopyrimidine dihydrochloride(39944-62-2)
• EPA Substance Registry System: 2,4,5,6-Tetraaminopyrimidine dihydrochloride(39944-62-2)

Safety Data

• Hazardous Substances Data: 39944-62-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4,5,6-Tetraaminopyrimidine dihydrochloride is used as a building block for the synthesis of various pharmaceutical drugs due to its unique chemical structure and reactivity. It contributes to the development of new medications with potential therapeutic effects.
Used in Research Laboratories:
In research settings, 2,4,5,6-Tetraaminopyrimidine dihydrochloride is utilized as a precursor for the synthesis of heterocyclic compounds. Its ability to form diverse chemical structures makes it a valuable tool in the exploration of new chemical entities and potential drug candidates.
Used in Medicinal Chemistry:
2,4,5,6-Tetraaminopyrimidine dihydrochloride is employed in medicinal chemistry for its potential applications in drug development. Its unique properties and reactivity allow for the creation of novel compounds with potential pharmacological effects.
Used in Drug Development:
The biological activities and potential pharmacological effects of 2,4,5,6-Tetraaminopyrimidine dihydrochloride have been studied, making it a promising candidate for drug development. Its use in the synthesis of various organic compounds and pharmaceutical drugs highlights its importance in the discovery of new therapeutic agents.

InChI:InChI=1/C4H8N6.2ClH/c5-1-2(6)9-4(8)10-3(1)7;;/h5H2,(H6,6,7,8,9,10);2*1H

Upstream product

• 5392-28-9 2,4,5,6-tetraaminopyrimidine sulfate 

Downstream Products

• 7761-75-3 2,4,7-Triamino-6-(2-furyl)-pteridin 
• 57521-63-8 2,4-diamino-6-chloromethylpteridine 
• 1026-36-4 2,4-Diamino-6-(phenyl)pteridine 
• 708-74-7 2,4-diamino-6-methylpteridine 
• 192587-18-1 2,4-diamino-6-(p-methoxyphenyl)pteridine 
• 30146-32-8 6-(4-chloro-phenyl)-pteridine-2,4-diamine 
• 1029-87-4 2,4-Diamino-7-methyl-6-phenyl-pteridin 
• 945-24-4 2,4-diamino-6-(hydroxymethyl)pteridine 
• 1402415-45-5 C₂₀H₁₇ClN₆O₂ 
• 1402415-47-7 C₂₀H₁₇FN₆O₂ 
• 1402415-49-9 C₂₀H₁₈N₆O₂ 
• 1402415-50-2 C₂₁H₁₇F₃N₆O₂ 
• 1402415-29-5 C₂₀H₁₇ClN₆O₂ 
• 1402415-31-9 C₂₀H₁₇FN₆O₂ 

Relevant articles and documents

Aminopterin dosage forms and methods for inflammatory disorders

Embodiments of the present invention provide dosage forms and methods for treating a patient with an inflammatory disorder with a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof, that achieve efficacy without concomitant toxicity. Within certain embodiments, the present invention provides a method for treating an inflammatory disorder in a patient with uninterrupted doses of aminopterin.

Compositions and methods employing aminopterin

The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.